1. Home
  2. OP vs ONCO Comparison

OP vs ONCO Comparison

Compare OP & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OP
  • ONCO
  • Stock Information
  • Founded
  • OP 2021
  • ONCO 2018
  • Country
  • OP Greece
  • ONCO United States
  • Employees
  • OP N/A
  • ONCO N/A
  • Industry
  • OP
  • ONCO Biotechnology: Pharmaceutical Preparations
  • Sector
  • OP
  • ONCO Health Care
  • Exchange
  • OP Nasdaq
  • ONCO Nasdaq
  • Market Cap
  • OP 8.3M
  • ONCO 3.6M
  • IPO Year
  • OP N/A
  • ONCO 2022
  • Fundamental
  • Price
  • OP $0.90
  • ONCO $0.13
  • Analyst Decision
  • OP
  • ONCO
  • Analyst Count
  • OP 0
  • ONCO 0
  • Target Price
  • OP N/A
  • ONCO N/A
  • AVG Volume (30 Days)
  • OP 12.0K
  • ONCO 2.1M
  • Earning Date
  • OP 04-10-2025
  • ONCO 04-10-2025
  • Dividend Yield
  • OP N/A
  • ONCO N/A
  • EPS Growth
  • OP N/A
  • ONCO N/A
  • EPS
  • OP N/A
  • ONCO N/A
  • Revenue
  • OP $25,729,000.00
  • ONCO $1,870,605.00
  • Revenue This Year
  • OP N/A
  • ONCO N/A
  • Revenue Next Year
  • OP N/A
  • ONCO N/A
  • P/E Ratio
  • OP N/A
  • ONCO N/A
  • Revenue Growth
  • OP 36.33
  • ONCO N/A
  • 52 Week Low
  • OP $0.88
  • ONCO $0.13
  • 52 Week High
  • OP $3.15
  • ONCO $21.40
  • Technical
  • Relative Strength Index (RSI)
  • OP 29.68
  • ONCO 18.44
  • Support Level
  • OP $0.88
  • ONCO $0.16
  • Resistance Level
  • OP $0.99
  • ONCO $0.25
  • Average True Range (ATR)
  • OP 0.06
  • ONCO 0.03
  • MACD
  • OP -0.01
  • ONCO -0.01
  • Stochastic Oscillator
  • OP 6.54
  • ONCO 1.56

About OP OceanPal Inc.

OceanPal Inc is a provider of shipping transportation services. It specializes in the ownership of vessels. Each of its vessels is owned through a separate wholly-owned subsidiary.

About ONCO Onconetix Inc.

Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.

Share on Social Networks: